Filgrastim biosimilar - Fuji Pharmaceutical/Mochida Pharmaceutical/Gene Techno Science

Drug Profile

Filgrastim biosimilar - Fuji Pharmaceutical/Mochida Pharmaceutical/Gene Techno Science

Alternative Names: Filgrastim BS; FSK-0808; GBS 001

Latest Information Update: 02 Apr 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Fuji Pharmaceutical; Gene Techno Science; Mochida Pharmaceutical
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants
  • Mechanism of Action Granulocyte colony stimulating factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Neutropenia

Most Recent Events

  • 08 Aug 2013 Biomarkers information updated
  • 15 Nov 2011 Biosimilar filgrastim is still in phase II/III trials for Neutropenia in Japan
  • 30 Jul 2010 Phase-II/III clinical trials in Neutropenia in Japan (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top